期刊文献+

地西他滨联合化疗治疗难治复发急性髓系白血病及骨髓增生异常综合征转化白血病的效果观察 被引量:13

Clinical effects of decitabine combined with chemotherapy in the treatment of patients with refractory and relapsed acute myeloid leukemia and myelodysplastic syndrome transformed leukemia
收藏 分享 导出
摘要 目的 探讨地西他滨联合化疗治疗难治复发急性髓系白血病(AML)及骨髓增生异常综合征(MDS)转化AML的临床效果.方法 选取2013年2月至2014年3月住院治疗的难治复发AML患者19例及MDS转化AML患者4例,所有患者给予地西他滨联合CAG方案进行治疗,评估患者治疗效果及不良反应.结果 经过1个疗程治疗后,14例(60.9%)完全缓解,2例(8.7%)部分缓解,7例(30.4%)无效,总有效率69.6%,不同染色体核型患者临床治疗效果差异具有统计学意义(P<0.05).23例患者出现不同程度的骨髓抑制,其中Ⅰ~Ⅱ级中性粒细胞减少2例,Ⅲ~Ⅳ级21例,中性粒细胞减少中位时间13 d;Ⅲ~Ⅳ级贫血23例;Ⅲ~Ⅳ级血小板减少23例,血小板减少中位时间16d.Ⅰ~Ⅱ级出血20例,Ⅲ~Ⅳ级3例.Ⅰ~Ⅱ级胃肠道反应1例.Ⅰ~Ⅱ级肝功能异常1例.所有患者随访至2014年3月31日,生存20例,死亡3例,中位总生存期3.1个月,1年累积生存率86%.结论 地西他滨联合化疗治疗难治复发AML及MDS转化白血病的临床缓解率高,不良反应少;染色体核型可能是影响治疗效果的重要因素. Objective To investigate the clinical effects of decitabine combined with chemotherapy in the treatment of patients with refractory and relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) transformed leukemia.Methods 19 patients with refractory and relapsed AML and 4 cases of patients with MDS transformed AML were enrolled from February 2013 to March 2014.All cases were treated with decitabine combined with CAG regimen.The clinical effects and adverse reactions were evaluated.Results After a course of treatment,14 cases (60.9 %) were complete remission,2 cases (8.7 %) were parrtial remission,7 cases (30.4 %) were non-remission,and the total efficiency rate was 69.6 %.The differences of clinical outcomes among different karyotypes were statistically significant (P 〈 0.05).There were varied degree of bone marrow suppression among 23 patient,including 2 cases were Ⅰ-Ⅱ grade,21 cases were Ⅲ-Ⅳ grade neutropenia.The neutrophil cells median reduce time was 13 d.23 cases were Ⅲ-Ⅳ grade anemia.23 cases were Ⅲ-Ⅳ grade thrombocytopenia.The Plt median reduce time was 16 d.20 cases were Ⅰ-Ⅱ grade bleeding,and 3 cases were lⅢ-Ⅳ grade.1 case was Ⅰ-Ⅱ grade gastrointestina reactions.1 case was Ⅰ-Ⅱ grade abnormal liver function.All patients were followed-up until March 31,2014,and 20 cases were survival,3 cases were deaths.The median overall survival time was 3.1 months,1-year cumulative survival rate was 86 %.Conclusions Decitabine combined with chemotherapy used in refractory and relapsed AML and MDS transformed leukemia has high clinical remission rate,and has fewer adverse reactions.Karyotype might be an important factor affecting the therapeutic effect.
作者 韩波 王朝晖 邵纬 王九河 洪青 范传波 刘俊玲 田猛 王海霞 乌庆超 Han Bo, Wang Zhaohui, Shao Wei, Wang Jiuhe, Hong Qing, Fan Chuanbo, Liu Junling, Tian Meng, Wang Haixia, Wu Qingchao. (Department of Hematology, Qingdao Haici Medical Group, Qingdao 266033, China)
出处 《白血病.淋巴瘤》 CAS 2014年第12期733-736,共4页 Journal of Leukemia & Lymphoma
关键词 白血病 髓样 急性 骨髓增生异常综合征转化白血病 难治 复发 地西他滨 药物疗法 Leukemia, myeloid, acute Myelodysplastic syndrome transformed leukemia Refractory Relapsed Decitabine Drug therapy
作者简介 通信作者:乌庆超,Email:qdhcwqc@163.com
  • 相关文献

参考文献18

  • 1Van der Reijden BA,Massop M,Simons A,et al.The NDE1 gene is disrupted by the inv(16) in 90% of cases with CBFB-MYH1 l-positive acute myeloid leukemia[J].Leukemia,2010,24:857-859. 被引量:1
  • 2Garcia-Manero G.Myelodysplastic syndromes:2012 update on diagnosis,risk-stratification,and management[J].Am J Hematol,2012,87:692-701. 被引量:1
  • 3Goldin LR,Kristinsson SY,Liang XS,et al.Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes[J].J Clin Oncol,2012,30:179-183. 被引量:1
  • 4Cermak J,Jonasova A,Vondrakova J,et al.A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes[J].Leuk Res,2013,37:1612-1615. 被引量:1
  • 5Ferrero D,Crisà E,Marmont F,et al.Survival improvement of poorprognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents[J].Ann Hematol,2014,93:1391-1400. 被引量:1
  • 6Jiang D,Hong Q,Shen Y,et al.The diagnostic value of DNA methylation in leukemia:a systematic review and meta-analysis[J].PLoS One,2014,9:e96822. 被引量:1
  • 7Chowdhury S,Seropian S,Marks PW.Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia[J].Am J Hematol,2009,84:599-600. 被引量:1
  • 8张秀群,邓银芬,张磊,戴丹,苏爱玲,张学忠,徐燕丽.地西他滨序贯半量CAG方案治疗中高危骨髓增生异常综合征及白血病转化四例[J].白血病.淋巴瘤,2012,21(7):433-435. 被引量:17
  • 9郝杰,王黎,王艳煜,刘振宇,顾潇,刘家琪,李良群,段云祎,陈瑜,赵维莅,沈志祥.地西他滨联合DAG方案等三种方案治疗复发、难治急性髓系白血病疗效的比较分析[J].中华血液学杂志,2014,35(6):481-485. 被引量:33
  • 10Zeng DF,Zhang J,Zhu LD,et al.Analysis of drug resistance-associated proteins expressions of patients with the recurrent of acute leukemia via protein microarray technology[J].Eur Rev Med Pharmacol Sci,2014,18:537-543. 被引量:1

二级参考文献64

共引文献62

同被引文献103

  • 1Deschamps,K.,Matricali,G.A.,Roosen,P,et al.Comparison of foot segmental mobility and coupling during gait between patients with diabetes mellitus with and without neuropathy and adults without diabetes [J].Clinical biomeehanics, 2013,28(7):813-819. 被引量:1
  • 2Richard Wakeford.The risk of leukaemia in young children from exposure to tritium and carbon-14 in the discharges of German nuclear power stations and in the fallout from atmospheric nuclear weapons testing [J].Radiation and En- vironmental Biophysics,2014,53(2):365-379. 被引量:1
  • 3房佰俊,李睿涵,刘丽娜,等.抗血管新生在慢性粒细胞白血病靶向治疗应用中的研究[C].//第八届中国肿瘤学术大会暨第十三届海峡两岸肿瘤学术会议论文集.2014:713-714. 被引量:1
  • 4Huang D, Nagata Y, Grossmann V, et al. BRCC3 mutations in myeloid neoplasms? [J]. Haemalologica, 2015, 100 (8): 1051- 1057. DOI : 10.3324/haematol.2014.111989. S. 被引量:1
  • 5ekeres MA, Cutler C. How we treat higher-risk myelodysplastic syndromes [J]. Blood, 2014, 123 (6): 829-836. DOI:10.1182/ blood-2013-08-496935. 被引量:1
  • 6Itzykson R, Fenaux P. Epigenetics of myelodysp|astic syndromes [J 1. Leukemia, 2014, 28(3): 497-506. DOI: 10.1038/leu.2013.343. 被引量:1
  • 7Leonard SM, Perry T, Woodman CB, et al. Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia [J]. PLoS One, 2014, 9 (1): e87475. DOI: 10.1371/joumal.pone.0087475. 被引量:1
  • 8中华医学会血液学分会.成人急性髓系白血病(非急性早幼粒细胞自血病)中国诊疗指南(2011年版)[J].中华血液学杂志,2011,3201):804-807. 被引量:1
  • 9陈书长.骨髓增生异常综合征的研究进展及其免疫治疗[J].癌症进展,2010(2):139-142. 被引量:3
  • 10刘春霞,姚小健,易娟,陈静,魏虎来.三氧化二砷联合FLAG方案治疗复发急性髓性白血病及对白血病干细胞的影响[J].中国肿瘤临床,2011,38(15):915-917. 被引量:7

引证文献13

二级引证文献30

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈